Innate Pharma Enters Exclusive License Agreement with Takeda
(24/7 MARKET NEWS) – Innate Pharma SA (NASDAQ:IPHA) announced, this morning, that it entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
Innate Pharma is trading at $3.24, up $0.39 (+13.68%), on 60 thousand premarket shares.
Its 52-week trading range is $1.90 to $3.97. It’s trading at a key inflection point and if it can break through this resistance, on strong trading volume, it may try to challenge the $4 trading level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.